title: Differential expression of type I cytokeratins in hamster cheek pouch epithelium following treatment with dimethylbenzanthracene.
abstract: Cytokeratin (CK) expression in untreated, paraffin-treated or dimethylbenzanthracene (DMBA)-treated hamster cheek pouch epithelium was investigated utilizing monoclonal antibodies AE1 or AE3, which react with type I or type II CKs, respectively, and by in situ hybridization utilizing type I CK-specific probes. The latter were isolated from a cDNA library of hamster cheek pouch mRNA and designated CK 13 and CK 10 based on their respective homologies (> 95% amino acids) with murine CK 13 and human CK 10. Treatment of hamster cheek pouch epithelium with DMBA resulted in increased expression of type I CK, detected immunohistochemically with monoclonal AE1, but decreased expression of type II CKs detected with AE3. Despite an overall increase in type I CKs, in situ hybridization demonstrated differential expression of type I CKs with altered distribution of CK 13 mRNA and reduced expression of CK 10 mRNA, providing additional sensitive markers for DMBA-associated changes in CKs. These changes were constant at 2 to 22 weeks in the pre-neoplastic and neoplastic epithelium following the initial application of DMBA.
authors.affiliation: Department of Restorative Dentistry, University of Otago, Dunedin, New Zealand.
authors.forename: B H
authors.initials: BH
authors.lastname: Shearer
authors.forename: M D
authors.initials: MD
authors.lastname: McMillan
authors.forename: H F
authors.initials: HF
authors.lastname: Jenkinson
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000009:adverse effects*; D000818:Animals; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D002273:Carcinogens / Q000009:adverse effects*; D006224:Cricetinae; D018076:DNA, Complementary; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D007633:Keratins / Q000032:analysis / Q000145:classification / Q000187:drug effects / Q000235:genetics*; D008297:Male; D051379:Mice; D009061:Mouth Mucosa / Q000187:drug effects* / Q000473:pathology; D009062:Mouth Neoplasms / Q000473:pathology; D011230:Precancerous Conditions / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis; D017386:Sequence Homology, Amino Acid
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D002273:Carcinogens; D018076:DNA, Complementary; D012333:RNA, Messenger; D015127:9,10-Dimethyl-1,2-benzanthracene; D007633:Keratins